Multidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Introduction: The Multidomain Alzheimer Preventive Trial (MAPT) assessed the efficacy of omega‐3 fatty acid supplementation, a multidomain intervention (MI), or a combination of both on cognition. Impact according to cerebral amyloid status was evaluated by PET scan. Methods: Participants were nondemented and had memory complaints, limitation in one instrumental activity of daily living, or slow gait. The primary outcome was a change from baseline in 36 months measured with a cognitive composite Z score. Results: No effect was observed on cognition in the negative amyloid group (n = 167). In the positive amyloid group (n = 102), we observed a difference of 0.708 and 0.471 in the cognitive composite score between the MI plus omega‐3 fatty acid group, the MI alone group, and the placebo group, respectively. Discussion: MI alone or in combination with omega‐3 fatty acids was associated with improved primary cognitive outcome in subjects with positive amyloid status. Trial Registration: ClinicalTrials.gov Identifier: NCT01513252.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Recent results of a phase Ib study evaluating the impact of aducanumab on brain amyloid burden and cognitive parameters (Mini-Mental State Examination [MMSE] and Clinical Dementia Rating [CDR]) are promising and appear to validate the use of amyloid biomarker assessment in preventive therapy trials [5].”
BackgroundVillemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“The negative results of bapineuzumab [2] and solanezumab [3] phase III trials were an important methodological turning point in AD therapeutic trials.”
BackgroundPhase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“The negative results of bapineuzumab [2] and solanezumab [3] phase III trials were an important methodological turning point in AD therapeutic trials.”
BackgroundSelf-citationUse of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Self-citationAndrieu, S., Guyonnet, S., Coley, N., Cantet, C., Bonnefoy, M., Bordes, S., Bories, L., Cufi, M.-N., Dantoine, T., Dartigues, J.-F., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30040-6 · Cited by 838
Self-citationPreclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 1×
“This result is consistent with the data in the literature which indicate that nondemented subjects with negative amyloid biomarkers show very slight cognitive decline [18].”
ResultFleisher, A. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.150 · Cited by 364
Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.03.007 · Cited by 147 · cited 1×
“Evidence of an amyloid signature is therefore now essential to include participants in therapeutic “disease-modifying” trials [4].”
BackgroundSelf-citation
Cited by
Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465
Chen, L., Hwang, A., Lee, W., Peng, L., Lin, M., Neil, D. L., Shih, S., Loh, C., Chiou, S., & Taiwan Health Promotion Intervention Study for Elders research group (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12534 · Cited by 134
Liang, C.-K., Lee, W.-J., Hwang, A.-C., Lin, C.-S., Chou, M.-Y., Peng, L.-N., Lin, M.-H., & Chen, L.-K. (2021) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2021.104392 · Cited by 45
Metadata
- Authors
- Delrieu, J., Payoux, P., Carrié, I., Cantet, C., Weiner, M., Vellas, B., & Andrieu, S.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2019-09-23
- Volume
- 15
- Issue
- 11
- Pages
- 1392-1401
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2975761185
- Cited by
- 45
- References
- 11
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status. https://app.cochat.ai/papers/10.1016/j.jalz.2019.07.008
- The paper
- Delrieu, J., Payoux, P., Carrié, I., Cantet, C., Weiner, M., Vellas, B., & Andrieu, S. (2019). Multidomain intervention and/or omega‐3 in nondemented elderly subjects according to amyloid status. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2019.07.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.